Výsledky vyhledávání

Use of Sickness Benefits by Patients With Metastatic Breast Cancer – A Swedish Cohort Study

Autor: U. Wilking, Elham Hedayati, Narsis A. Kiani, Aina Johnsson, Renske Altena, Sofie A. M. Gernaat

Background Advances in the treatment of metastatic breast cancer (mBC) have led to improved life expectancy. Many cancer survivors desire to return to paid work to enhance their sense of well-being. For patients with mBC, little is known about how th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7798aaa4d42389bc4bb5d92a12278982
https://doi.org/10.21203/rs.3.rs-605050/v1

Zobrazit plný text záznamu

Sickness absence and disability pension among swedish women prior to breast cancer relapse with a special focus on the roles of treatment and comorbidity

Autor: U. Wilking, Sofie A. M. Gernaat, Renske Altena, Aina Johnsson, Elham Hedayati

Publikováno v: European Journal of Cancer Care

Objective We aimed to determine the longitudinal prevalence and the predictors of sickness absence (SA) and disability pension (DP) in breast cancer (BC) women who eventually developed relapse. Methods A total of 1293 BC women, who were ages 20–63

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13ad1702405c873f0c42d10727c20be2
https://doi.org/10.1111/ecc.13353

Zobrazit plný text záznamu

Sickness absence and disability pension among Swedish women before breast cancer relapse

Autor: Sofie A. M. Gernaat, Hedayati Elham, Renske Altena, Aina Johnsson, U. Wilking

Publikováno v: Journal of Clinical Oncology. 38:e14121-e14121

e14121 Background: Sickness absence (SA) and disability pension (DP) from diagnosis of primary breast cancer (BC) among patients who in a later stage will develop a recurrence or metastatic disease is unknown. This study explores the prevalence and r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e67118ea3d418ed0964c38d7ade58363
https://doi.org/10.1200/jco.2020.38.15_suppl.e14121

Zobrazit plný text záznamu

Abstract P5-02-07: Distribution of biomarker evaluation scores among the pathology departments of Sweden: Comparison study of 35,066 breast cancer cases

Autor: Stephanie Robertson, Irma Fredriksson, U. Wilking, Balazs Acs, Johan Hartman

Publikováno v: Cancer Research. 80:P5-02

Background/Aim: Correct assessments of prognostic and predictive markers (ER, PgR, HER2, histological grade) are essential in the choice of adjuvant therapy in primary breast cancer. Comparisons of department performances are necessary to ensure that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d42aecc9cab3ad366eaa5a52bc08bc0
https://doi.org/10.1158/1538-7445.sabcs19-p5-02-07

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Drug utilization research in the area of cancer drugs

Autor: Nils Wilking, U. Wilking, Bengt Jönsson, Thomas Hofmarcher

Publikováno v: Drug Utilization Research

Increased biological understanding of cancer diseases has resulted in a paradigm shift in the medical treatment of cancer. Despite encouraging advances, most cancer types are still incurable and cancer is the second most common cause of death in deve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52a9373eb4bf3e344a4a56ab959a2be2
https://doi.org/10.1002/9781118949740.ch30

Zobrazit plný text záznamu

Abstract P1-09-05: Re-Testing of HER2 Status in Recurring Metastatic Breast Cancer Is a Clinically Relevant and Cost-Effective Strategy

Autor: Jonas Bergh, M. Bernow, U. Wilking, Nils Wilking, B. Jonsson

Publikováno v: Cancer Research. 70:P1-09

Introduction Previously HER2 status has been shown to change in 6 to 30% of recurring metastatic breast cancer (RMBC) patients (pts). Still most clinicians base trastuzumab (TZ) re-treatment decisions on prior HER2 testing of the primary tumor. This

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f6f6d02e927a6672e77582ba5d4fe44
https://doi.org/10.1158/0008-5472.sabcs10-p1-09-05

Zobrazit plný text záznamu

Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden

Autor: Jonas Bergh, Bengt Jönsson, U. Wilking, Nils Wilking

Publikováno v: Acta Oncologica. 49:844-850

Approximately 14% of Early Breast Cancers, EBCs, and 25% of Metastatic BCs, MBCs, are HER2 positive. There is an effective treatment (trastuzumab) for both EBC (9% increased absolute disease free survival at five years) and MBC (five to nine months'

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c28ae71800cdbd60dae34bf76b3da78d
https://doi.org/10.3109/0284186x.2010.492790

Zobrazit plný text záznamu

Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status

Autor: U. Wilking, Peter Lindgren, Bengt Jönsson, Nils Wilking

Publikováno v: Journal of Clinical Oncology. 35:6535-6535

6535 Background: As new cancer drugs come at a high cost, it is of interest to examine if drugs with high impact on survival has a relative higher uptake compared to drugs with limited impact on survival in countries with limited resources (low Gross

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b583be2d5be9b9315d30b2970a4708fb
https://doi.org/10.1200/jco.2017.35.15_suppl.6535

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání